Investigating white blood cells to develop new therapies for autoimmune diseases
Official title: Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
Run by Quell Therapeutics Limited · NCT04838171 · Data updated 2026-11-12
This study is trying to learn more about white blood cells from volunteers to help create new treatments for autoimmune diseases.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Quell Therapeutics Limited Industry-sponsored |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | March 24, 2021 |
| Main results expected | December 31, 2029 |
| Study ends | January 2030 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT04838171 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy volunteers willing to donate white blood cells.
✕Probably not a fit
Patients with active autoimmune diseases or those requiring immediate treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze white blood cells from volunteer donors to aid in the development of engineered regulatory T cell therapies. By understanding the characteristics and functions of these cells, researchers hope to enhance treatments for conditions such as autoimmune diseases and organ rejection. The study will involve blood collection from participants, with no additional eligibility criteria imposed beyond those set by the consenting institutions.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that improve outcomes for patients with autoimmune diseases and organ transplant rejections.
How similar studies have gone: While similar studies have explored the use of white blood cells in therapy development, this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
Where it's running
-
Quell Investigator Site 01
London, United Kingdom Recruiting
Study contacts
- Study coordinator: Gareth Wright
- Email: contact@quell-tx.com
- Phone: +4(0)2070969012
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using gene analysis to improve diagnosis of liver transplant rejection
This study is testing whether analyzing specific genes in liver transplant patients can help doctors diagnose rejection faster and more accurately.
-
Analyzing liver grafts to predict transplant outcomes
This study is testing if certain markers in liver grafts can help predict how well the transplant will work for patients receiving the liver.
-
Finding the right steroid dose for acute T cell rejection after kidney or kidney–pancreas transplant
This trial will test whether lower doses of steroids work as well as higher doses to treat acute T cell–mediated rejection in people who have had a kidney or simultaneous kidney–pancreas transplant.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
Immune biomarkers to predict complications after liver transplantation
This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.